Hepatitis B Therapeutics Market by Application and Geography - Forecast and Analysis 2022-2026

The hepatitis B therapeutics market share is expected to increase by USD 471.49 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 3.29%.

This hepatitis B therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hepatitis B therapeutics market segmentations by application (drugs and vaccines) and geography (North America, Europe, APAC, and Rest of World (ROW)). The hepatitis B therapeutics market report also offers information on several market vendors, including ABIVAX, Biotest AG, Bristol Myers Squibb Co., CASI Pharmaceuticals Inc., Cipla Ltd., Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Healthcare Ltd., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Emergent BioSolutions Inc. among others.

What will the Hepatitis B Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Hepatitis B Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Hepatitis B Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing prevalence of hepatitis B in infants is notably driving the hepatitis B therapeutics market growth, although factors such as stringent regulations may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hepatitis B therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Hepatitis B Therapeutics Market Driver

The increasing prevalence of hepatitis B in infants is one of the key drivers supporting the hepatitis B therapeutics market growth. Infants who get hepatitis B become chronically infected, and about 1 out of 4 of them die within a short period. Hepatitis B virus-infected pregnant woman can pass the virus to her infant at birth if the baby is not vaccinated. To resolve this issue, in the US and many other developed countries, all pregnant women are routinely screened for hepatitis B. Meanwhile, all infants born to mothers with hepatitis B should get the first vaccine dose within 12 hours of birth and complete the series of shots. Therefore, due to the increase in the prevalence of hepatitis B in infants, the companies are developing various vaccines and drugs against the hepatitis B virus. This leads to an increase in the global hepatitis B therapeutics market growth during the forecast period.

Key Hepatitis B Therapeutics Market Trend

New technological advancements is one of the key hepatitis B therapeutics market trends that is contributing to the market growth. For instance, Scientists of Imperial College London developed the concept of organ-on-a-chip technology, which creates an actual human organ environment for the virus to act upon. They have come up with a model of the artificial liver, which was infected by hepatitis B, to find out the impact of the virus closely and the symptoms it is generating. Also, the organ that was developed artificially on the chip has a longer life span of at least 40 days so that the scientists can observe the whole life cycle of the virus and how it is impacting the organ at which stage. These types of new technology advancements aimed at early diagnosis and treatment of hepatitis B will drive the global hepatitis B therapeutics market over the forecast period.

Key Hepatitis B Therapeutics Market Challenge

Stringent regulations is one of the factors hindering the hepatitis B therapeutics market growth. For instance, in November 2018, Dynavax Technologies received the Complete Response Letter (CRL) from the US FDA regarding its Biologics License Application (BLA) for the HEPLISAV-B hepatitis B vaccine. The CRL seeks information regarding several topics, including clarification regarding specific adverse events of special interest (AESI), a numerical imbalance in a small number of cardiac events, new analyses of the integrated safety data, and post-marketing commitments. Later, the company provided all the required information to the US FDA and received the approval, but the actual approval timeline was delayed due to the CRL. Such type of stringent regulations delays the approval timelines, and the sponsors need to wait for a long time to get approval from the regulatory agencies. Hence, these stringent regulations from the regulatory agencies are expected to hamper the global hepatitis B therapeutics market over the forecast period.

This hepatitis B therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global hepatitis B therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hepatitis B therapeutics market during the forecast period.

Who are the Major Hepatitis B Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• ABIVAX
• Biotest AG
• Bristol Myers Squibb Co.
• CASI Pharmaceuticals Inc.
• Cipla Ltd.
• Dynavax Technologies Corp.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Hetero Healthcare Ltd.
• Johnson and Johnson
• Merck and Co. Inc.
• Novartis AG
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Emergent BioSolutions Inc.

 

This statistical study of the hepatitis B therapeutics market encompasses successful business strategies deployed by the key vendors. The hepatitis B therapeutics market is fragmented and the vendors are deploying growth strategies such as price, quality, innovation, reputation, and distribution to compete in the market.

Product Insights and News

• Biotest AG - The therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, hematological diseases, and in intensive care medicine. 
• Biotest AG - The company offers hepatitis B therapeutics products such as prophylaxis. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The hepatitis B therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Hepatitis B Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the hepatitis B therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Hepatitis B Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

51% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for hepatitis B therapeutics market in North America. Market growth in this region will be slower than the growth of the market in APAC.

The increasing incidence of HBV infections will facilitate the hepatitis B therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 reduced the demand for hepatitis B diagnostics in North America. However, the market is expected to recover during the forecast period due to the ongoing large-scale vaccination drives, which will contain the spread of COVID-19, and the resumption of manufacturing activities post the lifting of lockdowns.

What are the Revenue-generating Application Segments in the Hepatitis B Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The hepatitis B therapeutics market share growth by the drugs segment will be significant during the forecast period. The growth of the drugs segment is also driven by the recent product approvals and new technological advancements in the treatment of hepatitis B. For instance, in September 2020, MYR Pharmaceuticals launched HEPCLUDEX in Germany, France, and Austria for the treatment of chronic hepatitis delta virus (HDV) infection and compensated liver disease. The increasing expenditure on R and D by various organizations to develop technologies to diagnose the disease and to identify at which stage the virus is causing infection to the liver is increasing the demand for target-specific drugs. Therefore, the continuous initiatives by organizations and recent approvals of drugs for the treatment of hepatitis B are driving the growth of the market.

This report provides an accurate prediction of the contribution of all the segments to the growth of the hepatitis B therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Hepatitis B Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 3.29%
Market growth 2022-2026	$ 471.49 million
Market structure	Fragmented
YoY growth (%)	2.98
Regional analysis	North America, Europe, APAC, and Rest of World (ROW)
Performing market contribution	North America at 51%
Key consumer countries	US, Canada, Brazil, China, and Germany
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	ABIVAX, Biotest AG, Bristol Myers Squibb Co., CASI Pharmaceuticals Inc., Cipla Ltd., Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Healthcare Ltd., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Emergent BioSolutions Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Hepatitis B Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive hepatitis B therapeutics market growth during the next five years
• Precise estimation of the hepatitis B therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hepatitis B therapeutics industry across North America, Europe, APAC, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of hepatitis B therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch